The retrospective study reviewed outcomes for 42 patients who underwent knee replacement surgery. These patients were divided into two groups:
NeeHab Users: Patients who used the self-administered motion device alongside standard PT.
Control Group: Patients who relied solely on manual PT.
Each group consisted of 21 patients treated by the same surgeon and physical therapist, ensuring consistency in care. The goal? To evaluate which method helped patients achieve better range of motion and faster recovery.
Key Findings
Improved Range of Motion: NeeHab users consistently achieved greater ROM at every post-operative check. By week 6, they reached an average ROM of 124°, surpassing the control group’s 121° at week 12.
Faster Progress: NeeHab users reached their range of motion goals sooner, potentially allowing them to return to normal activities earlier.
Reduced Need for PT: Over half of the NeeHab group didn’t require a 12-week PT session, suggesting that the device could lower overall healthcare costs.
Why NeeHab Stands Out
Use it Anywhere: NeeHab is lightweight and easy to use at home or on-the-go, so you don’t have to depend entirely on therapy visits.
Gentle Yet Effective: Designed with soft, adjustable straps, NeeHab makes it easy to stretch and strengthen your knee without added discomfort.
Cost Efficiency: Fewer PT sessions mean lower recovery costs without compromising results.
Feel Empowered: NeeHab makes it simple to take charge of your recovery, so you feel confident and in control every step of the way.
Conclusions in the Clinical Study
The study highlights NeeHab as a game-changer for knee replacement recovery. With its ability to enhance ROM, reduce recovery time, and empower patients to take control of their rehabilitation, NeeHab offers a practical alternative to only using traditional PT as a solution.
Whether you're planning to have knee surgery or exploring ways to improve recovery, this innovative device could help you get back on your feet — faster and with less pain.
Click here to learn more about NeeHab’s New Clinical Study: 2024 Retrospective Study
Comments